Pfizer and Serum Institute of India have both applied to the Drugs Controller General of India (DCGI) seeking emergency use authorisation for their respective COVID-19 vaccine in India. This comes days after the United Kingdom and Bahrain formally approved the Pfizer-BioNTech COVID-19 vaccine for emergency use.
Meanwhile, Bharat Biotech’s Phase-3 clinical trial design for its candidate Covaxin expects 130 COVID-19 infections among trial participants, according to details shared by the company on the government’s clinical trial website. This clarification comes after news of Haryana Health Minister Anil Vij testing positive for COVID-19 two weeks after being vaccinated as a trial participant set off a bout of panic.
You can track coronavirus cases, deaths and testing rates at the national and State levels here. A list of State Helpline numbers is available as well.
Here are the updates:
About 130 Covaxin trial volunteers may test positive, says Bharat Biotech
Vaccine maker
